Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02967432 · ClinicalTrials.gov registry record · Phase 2
Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU
A Phase 2 study of Staphylococcus, sponsored by Crouse Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 216
- Enrollment target
- 1
- Study location
NCT02967432 is a Phase 2 study of Staphylococcus that has completed, run by Crouse Hospital. The registered enrollment target is 216 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02967432, a Phase 2 study of Staphylococcus, has completed, sponsored by Crouse Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 216 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether or not mupirocin treatment results in S. aureus decolonization in affected NICU patients.
Conditions Studied
Interventions
- DRUG Mupirocin Topical Ointment
- DRUG Petroleum Jelly
Study Locations (1)
New York
- Crouse Hospital - Neonatal Intensive Care Unit - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2016-10 |
| Est. Completion | 2019-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02967432
The ClinicalTrials.gov registry entry for NCT02967432 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Crouse Hospital, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Staphylococcus appearing as the primary indexed condition, and to 2 interventions - of which Mupirocin Topical Ointment is the first listed.
NCT02967432 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02967432 about?
NCT02967432 is a clinical study titled "Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU". The purpose of this study is to determine whether or not mupirocin treatment results in S. aureus decolonization in affected NICU patients.
What is the current status of trial NCT02967432?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 216 participants. The study started on 2016-10. Estimated completion is 2019-12.
What conditions does trial NCT02967432 study?
This clinical trial studies the following conditions: Staphylococcus.
What interventions are being tested in trial NCT02967432?
The interventions under investigation include: Mupirocin Topical Ointment (DRUG), Petroleum Jelly (DRUG).
Who is sponsoring clinical trial NCT02967432?
This trial is sponsored by Crouse Hospital, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02967432 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.